Dimerix

Dimerix Change in Working Capital

The Change in Working Capital of Dimerix (DXB.AX) as of Oct 19, 2026 is -24.03 M AUD. In the previous year, Change in Working Capital was 50.59 M AUD — a change of -147.50% (lower).

Change in Working Capital

-24.03 MAUD

YoY

-147.50%

Last updated:

Change in Working Capital of Dimerix is 2026 -24.03 M AUD. Change in Working Capital of Dimerix was 2025 50.59 M AUD. It decreases by -147.50% lower compared to the previous year.

The Dimerix Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2019
-371,471.00 AUD
Jan 1, 2020
-399,329.00 AUD
Jan 1, 2021
-237,199.00 AUD
Jan 1, 2022
-2.34 M AUD
Jan 1, 2023
531,998.00 AUD
Jan 1, 2024
7.97 M AUD
Jan 1, 2025
50.59 M AUD
Jan 1, 2026
-24.03 M AUD
The Dimerix Change in Working Capital history
YEARChange in Working CapitalYoY
-24.03 MAUD-147.50%
50.59 MAUD+534.68%
7.97 MAUD+1,398.35%
531,998.00AUD-122.76%
-2.34 MAUD+885.28%
-237,199.00AUD-40.60%
-399,329.00AUD+7.50%
-371,471.00AUD+13.84%
-326,307.00AUD+177.19%
-117,721.00AUD-48.82%
-230,036.00AUD-1,059.44%
23,976.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

Change in Working Capital of Dimerix is -24.03 M AUD in 2026.

Change in Working Capital of Dimerix changed from 50.59 M AUD to -24.03 M AUD, representing a -147.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital Dimerix since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's Dimerix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Dimerix

All Key Metrics — Dimerix